CARB-X provides additional funds for phage lysin to treat Pseudomonas

Contrafect Corporation announced yesterday that it has received an additional $2.3 million in funding over the next 2 years from CARB-X for the development of a phage lysin therapy to treat drug-resistant Pseudomonas aeruginosa infections.

Article: CIDRAP